Clinical Trials Logo

Hepatic Fibrosis clinical trials

View clinical trials related to Hepatic Fibrosis.

Filter by:

NCT ID: NCT01783314 Recruiting - Hepatic Fibrosis Clinical Trials

Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium

Start date: December 2010
Phase: Phase 4
Study type: Interventional

When someone has hepatitis C or some other condition that causes liver injury, he or she can develop a condition called liver fibrosis that over time, can cause the liver to stop working normally. Currently, the best way to determine the degree of fibrosis is to do a liver biopsy. The investigators hope to show that measuring the degree of liver fibrosis using an MRI with gadoxetate disodium is as good as or better than obtaining this information by performing a liver biopsy. Gadoxetate disodium is a contrast solution given through the veins that is considered safe, is approved for use by the Food and Drug Administration, and is already routinely given to patients with various forms of liver disease, including fibrosis.

NCT ID: NCT01447667 Completed - Clinical trials for Hepatocellular Carcinoma

Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA)

MRE
Start date: October 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to determine: - The efficacy of MRE score as a predictor of HCC recurrence within 2 years after RFA treatment - The efficacy of each indicator (MRE score, non-invasive serum markers) compared to the gold-standard histology score predicting hepatic fibrosis

NCT ID: NCT00466336 Completed - Cirrhosis Clinical Trials

Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices

Start date: January 2003
Phase: N/A
Study type: Observational

The purpose of our prospective study was to evaluate the value of Doppler parameters and compare the diagnostic accuracy of Doppler parameters with various biochemical indices in predicting significant hepatic fibrosis (≥ F2) and cirrhosis (F4) in chronic hepatitis C (CHC) patients.

NCT ID: NCT00466271 Completed - Chronic Hepatitis C Clinical Trials

Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study

Start date: April 2007
Phase: N/A
Study type: Observational

The purpose of the study is to validate the diagnostic accuracy and reproducibility of SAPI to predict significant hepatic fibrosis in HCV patients with PNALT who are scheduled to receive combination therapy with pegylated interferon plus ribavirin and percutaneous liver biopsies.